20th Feb 2014 12:48
LONDON (Alliance News) - GlaxoSmithKline PLC said Thursday that its treatment for chronic obstructive pulmonary disease Anoro had been recommended for marketing authorisation from the European Medicines Agency's committee for Medical Products for Human Use.
Glaxo expects a final decision on marketing authorisation for the product from the European Commission during the second quarter of 2014.
Anoro was developed in collaboration with Theravance Inc.
"Today's positive opinion is a step towards us making this important new medicine available. We are looking forward to the final decision of the European Commission in the near future," said Glaxo's President of Pharmaceuticals Research and Development Patrick Vallance in a statement.
Shares in Glaxo were trading up 0.08% at 1,683.00 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @hanassallnews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline